AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04968613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo monotherapy
Description: In addition to basic treatment, the patient also received selegiline treatment
Study NCT03354598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem-Etzadroxil/Probenecid
Description: Treatment of uncomplicated urinary tract infection
Study NCT03354598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Treatment of uncomplicated urinary tract infection
Study NCT01204567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
Study NCT01524120 — intervention group
Intervention type: DEVICE
Intervention: Endomicroscopy (iCLE, Pentax, Tokyo, Japan)
Description: Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
Study NCT03855982 — intervention group
Intervention type: DRUG
Intervention: Drug inducing myocarditis
Description: Drugs susceptible to induce myocarditis
Study NCT00244101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISX Group
Description: Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
Study NCT05727982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples, Biological samples analysis, Cardiology visit.
Description: These interventions are important to study all patients recruited
Study NCT03161080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neovis Total Multi® Eye Drops
Description: Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
Study NCT03161080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vismed Multi® Eye Drops
Description: Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
Study NCT03161080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrabak® Eye Drops
Description: Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
Study NCT02247102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).
Study NCT04545645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: median nerve mobilization
Description: The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
Study NCT04545645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neural stress provocation with cognitive auditory distraction
Description: Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
Study NCT04545645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing neural stress with a motor distraction
Description: The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
Study NCT04545645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neural stress provocation with auditory and motor cognitive distraction.
Description: The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
Study NCT02160262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
Study NCT04054531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: IV infusion
Study NCT04139928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium citrate or magnesium oxide
Description: Single-dose (300 mg) of magnesium citrate or magnesium oxide
Study NCT04139928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04054531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT01471548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT04560634 — intervention group
Intervention type: DRUG
Intervention: Norepinephrine
Description: Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
Study NCT04560634 — intervention group
Intervention type: DEVICE
Intervention: ClearSight®, Edwards Lifescience, Irvine, CA
Description: All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis.
Study NCT02306512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: H&E
Description: Sample will be stained with H\&E according to standard procedures
Study NCT02306512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IHC MART-1
Description: Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
Study NCT02306512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IF MART-1
Description: Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
Study NCT02306512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IF cocktail
Description: The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
Study NCT03231787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Platelet function assay
Description: Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours.
Study NCT00234988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine hydochloride monohydrate
Description: 10 mg QD with the option to increase dose to 15 mg QD up until Week 4
Study NCT05850169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Dance Therapy
Description: After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015).
Study NCT04589676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naloxone training
Description: The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
Study NCT04589676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone training
Description: The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
Study NCT01304004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satiety
Description: Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)
Study NCT01304004 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satiety
Description: Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)
Study NCT03394586 — intervention group
Intervention type: DRUG
Intervention: Exposure to golimumab
Description: retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
Study NCT01814501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study NCT01514461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Study NCT01514461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Study NCT01514461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Study NCT02245087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg of atorvastatin daily
Study NCT01200069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
Study NCT01200069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen intravenous
Description: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
Study NCT00004932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT01609504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ELRR BY TEM
Description: The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
Study NCT01609504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LTME
Description: LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
Study NCT01618825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2 x 25 mg tablet once a day
Study NCT01618825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: 2 x 25 mg tablet once a day
Study NCT04054531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT04054531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT01578577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHMI
Description: The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
Study NCT03672136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
Study NCT03672136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
Study NCT04054856 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Body Sensor Network
Description: The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person.
Study NCT00992849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
Study NCT00988845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol
Description: 200 mg bid po X 8 weeks
Study NCT01578577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Educator + EHMI
Description: This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
Study NCT02189291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate catheter removal
Description: The indwelling catheter will be removed prior to exiting the operating room.
Study NCT02189291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post op day 1 catheter removal
Description: For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
Study NCT01827462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent, inactivated influenza vaccine (TIV)
Description: Licensed Seasonal Influenza Vaccine TIV
Study NCT01827462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent, inactivated influenza vaccine (IIV4)
Description: Licensed Seasonal Influenza Vaccine IIV4
Study NCT01827462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Description: Licensed Seasonal High-Dose Influenza Vaccine TIV
Study NCT01738516 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography
Description: Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
Study NCT01738516 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography and additional experimental tasks
Description: Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
Study NCT02185443 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: * 60Gy in 3 fractions (20Gy/fraction) over 14 days~* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above
Study NCT03986905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Nasal Gel
Description: All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
Study NCT03986905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine Nasal Gel
Description: All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
Study NCT03986905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo nasal gel + placebo patch
Study NCT03986905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo nasal gel + placebo patch
Study NCT03986905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo nasal gel + placebo patch
Study NCT02873806 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantation of two iStent inject micro-bypass stents
Description: - Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
Study NCT02873806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical travoprost
Description: - Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
Study NCT02873806 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Two iStent inject micro-bypass stents
Description: - Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
Study NCT02873806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin
Description: Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) .
Study NCT03587441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine Methylsulfate
Description: 20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
Study NCT03587441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Description: intrathecal
Study NCT03587441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: intrathecal
Study NCT04348032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
Description: Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.